Explore 290 Genitourinary Licensing Deals - Payment Terms, Trends, and SEC-Filed Contracts
Yahoo4 days ago
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.
Fully revised and updated, the report provides details of 290 genitourinary deals from 2016 to 2025.Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of genitourinary deals listed by therapeutic target.The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse genitourinary collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Genitourinary Collaboration and Licensing Deals includes:
Trends in genitourinary dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of genitourinary deal records covering pharmaceutical and biotechnology
The leading genitourinary deals by value
Most active genitourinary licensing dealmakers
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in genitourinary dealmaking2.1. Introduction2.2. Genitourinary partnering over the years2.3. Genitourinary partnering by deal type2.4. Genitourinary partnering by industry sector2.5. Genitourinary partnering by stage of development2.6. Genitourinary partnering by technology type2.7. Genitourinary partnering by therapeutic indicationChapter 3 - Financial deal terms for genitourinary partnering3.1. Introduction3.2. Disclosed financials terms for genitourinary partnering3.3. Genitourinary partnering headline values3.4. Genitourinary deal upfront payments3.5. Genitourinary deal milestone payments3.6. Genitourinary royalty ratesChapter 4 - Leading genitourinary deals and dealmakers4.1. Introduction4.2. Most active in genitourinary partnering4.3. List of most active dealmakers in genitourinary4.4. Top genitourinary deals by valueChapter 5 - Genitourinary contract document directory5.1. Introduction5.2. Genitourinary partnering deals where contract document availableChapter 6 - Genitourinary dealmaking by therapeutic target6.1. Introduction6.2. Deals by genitourinary therapeutic targetDeal directoryDeal directory - Genitourinary deals by company A-Z 2016 to 2025Deal directory - Genitourinary deals by technology type 2016 to 2025Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/jhxqgf
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.
Fully revised and updated, the report provides details of 290 genitourinary deals from 2016 to 2025.Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of genitourinary deals listed by therapeutic target.The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse genitourinary collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Genitourinary Collaboration and Licensing Deals includes:
Trends in genitourinary dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of genitourinary deal records covering pharmaceutical and biotechnology
The leading genitourinary deals by value
Most active genitourinary licensing dealmakers
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in genitourinary dealmaking2.1. Introduction2.2. Genitourinary partnering over the years2.3. Genitourinary partnering by deal type2.4. Genitourinary partnering by industry sector2.5. Genitourinary partnering by stage of development2.6. Genitourinary partnering by technology type2.7. Genitourinary partnering by therapeutic indicationChapter 3 - Financial deal terms for genitourinary partnering3.1. Introduction3.2. Disclosed financials terms for genitourinary partnering3.3. Genitourinary partnering headline values3.4. Genitourinary deal upfront payments3.5. Genitourinary deal milestone payments3.6. Genitourinary royalty ratesChapter 4 - Leading genitourinary deals and dealmakers4.1. Introduction4.2. Most active in genitourinary partnering4.3. List of most active dealmakers in genitourinary4.4. Top genitourinary deals by valueChapter 5 - Genitourinary contract document directory5.1. Introduction5.2. Genitourinary partnering deals where contract document availableChapter 6 - Genitourinary dealmaking by therapeutic target6.1. Introduction6.2. Deals by genitourinary therapeutic targetDeal directoryDeal directory - Genitourinary deals by company A-Z 2016 to 2025Deal directory - Genitourinary deals by technology type 2016 to 2025Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/jhxqgf
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
18 minutes ago
- Bloomberg
Wise Turned to US as Some Investors Pushed Back on Dual Shares
Wise Plc's plan to shift its primary listing out of London gathered momentum after some existing shareholders rebuffed a proposal that would have allowed Chief Executive Officer Kristo Käärmann to keep his so-called golden shares for many more years, according to people familiar with the matter. In late 2024, Wise's board began consulting with shareholders on a plan that would allow the company to preserve in London the dual-class share structure that gives Käärmann de facto voting control in the company, the people said, asking not to be identified discussing non-public information.
Bloomberg
18 minutes ago
- Bloomberg
Centerbridge Partners Seeks Ways to Break to Price Deadlocks
Hi, it's Swetha Gopinath in London, speaking with the co-founder of alternative investment firm Centerbridge Partners. Also today, a $200 billion railroad takes shape after decades of M&A dreams. Today's top stories
Bloomberg
18 minutes ago
- Bloomberg
Bankers Prep Up To €2 Billion Debt for DSM Animal Nutrition Unit
Bankers are willing to lend up to €2 billion ($2.3 billion) for DSM-Firmenicgh AG's animal nutrition and health business, as the sale process draws closer to a conclusion. Final bids for the unit are expected this month, according to people familiar with the matter, who asked not to be identified because the talks are private. Bankers are working out how much debt could be made available to back a bid, they added.
